An open-label, two period, fixed sequence study of healthy subjects to assess the effect of repeat oral dosing of [Rifampin] on the pharmacokinetics of a single oral dose of [GW679769] (casopitant).

Trial Profile

An open-label, two period, fixed sequence study of healthy subjects to assess the effect of repeat oral dosing of [Rifampin] on the pharmacokinetics of a single oral dose of [GW679769] (casopitant).

Completed
Phase of Trial: Phase I

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Casopitant (Primary) ; Rifampicin
  • Indications Anxiety disorders; Chemotherapy-induced nausea and vomiting; Depressive disorders; Postoperative nausea and vomiting; Tuberculosis
  • Focus Pharmacokinetics
  • Sponsors GlaxoSmithKline
  • Most Recent Events

    • 26 Jan 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top